1
|
Spasov AA, Grechko OI, Eliseeva NV, Lifanova YV, Aleksandrenkova AN. Effect of adjuvant drugs on the analgesic activity of opioid morphine analgesics and compound RU-1205. RESEARCH RESULTS IN PHARMACOLOGY 2021. [DOI: 10.3897/rrpharmacology.7.68025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Introduction: Adjuvant medications can be used to increase the analgesic effect of opioid analgesics, reduce the manifestation of side effects, and also for premedication. This paper provides information on the effect of clonidine, haloperidol, metocloparmide, diazepam, midazolam on opioid analgesics: - morphine and the selective kappa-opioid agonist compound RU-1205.
Materials and methods: A probable interaction between RU-1205, morphine and adjuvant drugs in pain behaviors was carried out on the model of somatogenic pain. 95 male mice received either RU-1205 (5 mg/kg, i.p.) and morphine (1 mg/kg, i.p.) separately or in combination with haloperidol (0.45 mg/kg, i.p.); midazolam (0.3 mg/kg, i.p.); diazepam (1 mg/kg, i.p.); metoclopramide (5 mg/kg, i.p.), and clonidine (1 mg/kg, i.p.). The analgesic effect was assessed by tail flick test. Registration of the latent period of the reaction was carried out 30, 60 and 90 minutes after the adjuvant drug administration.
Results: When studying the interaction with morphine, it was found that clonidine, haloperidol and metoclopramide enhanced the effects; diazepam offset them, and midazolam had no affect on the analgesic properties. In the course of the studies, RU-1205 showed an increase in analgesic activity when combined with clonidine, a slight increase with midazolam, and a decrease when co-administered with diazepam. Haloperidol had no influence on the effect of RU-1205, while metoclopramide both potentiated and reduced the analgesic effect.
Discussion: Pharmacodynamic and pharmacokinetic interactions of RU-1205 with an α2AR agonist, benzodiazepine receptor agonists, D2P antagonist, and σ-receptor blocker were established.
Conclusion: The presented data make it possible to more accurately formulate ideas about the localization and action mechanism of the kappa-agonist of opioid receptors, the compound RU-1205.
Collapse
|
2
|
Role of Estradiol in the Regulation of Prolactin Secretion During Late Pregnancy. Neurochem Res 2016; 41:3344-3355. [DOI: 10.1007/s11064-016-2067-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2016] [Revised: 09/06/2016] [Accepted: 09/15/2016] [Indexed: 12/18/2022]
|
3
|
Bruna FA, de Di Nasso EG, Soaje M, Deis RP, Carón RW. Participation of opioid peptides in sucking-induced oxytocin and prolactin secretions in lactating goats. Reprod Domest Anim 2009; 45:796-802. [PMID: 19416483 DOI: 10.1111/j.1439-0531.2009.01354.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The role of opioid peptides in the secretion of oxytocin (OT) and prolactin (PRL) induced by sucking was studied in goats. Seven goats were isolated with their kids (four singletons and three twins) in individual corrals 3-4 weeks after parturition. On day 1 of the experiment, the kids were separated from the does for 7 h and were weighed before and 15 min after being reunited with their mothers to assess the amount of milk obtained by sucking. The does were blood-sampled 10 min before and at the end of the sucking period. On day 2, a similar protocol was followed, but naloxone was given immediately after the first blood sample. On day 3, the protocol was repeated but saline vehicle was injected instead of naloxone. On day 5, the naloxone experiment was repeated as on day 2. Milk ejection was evaluated as the difference in the weight of the kids before and after sucking for 15 min, and the maternal serum levels of OT and PRL were measured by radioimmunoassay. A significant decrease in the weight gain of the kids was obtained when the mothers were treated with naloxone on day 2. Consistently, serum levels of OT and PRL induced by sucking were significantly reduced; indicating that sucking-induced OT secretion for milk ejection in lactating goats is facilitated by opioid peptides. In a second experiment performed in the same animals 10 days later, the administration of OT, immediately after naloxone administration, prevented the decrease in the weight gain induced by naloxone, suggesting that the effect of the opioid antagonist on milk ejection in goats is a result of a reduced OT secretion. The results of this study confirm the importance of sucking-induced OT secretion for milk ejection in lactating goats, and indicate that OT and PRL secretion are regulated by opioid peptides in this species.
Collapse
Affiliation(s)
- F A Bruna
- Laboratorio de Fisiopatología Mamaria y Ovárica, IMBECU, CONICET, CCT-Mendoza, Mendoza, Argentina In Memoriam
| | | | | | | | | |
Collapse
|
4
|
Soaje M, Valdez S, Bregonzio C, Penissi A, Deis RP. Dopaminergic mechanisms involved in prolactin release after mifepristone and naloxone treatment during late pregnancy in the rat. Neuroendocrinology 2006; 84:58-67. [PMID: 17090971 DOI: 10.1159/000096825] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/18/2006] [Accepted: 09/08/2006] [Indexed: 02/03/2023]
Abstract
BACKGROUND/AIMS During late pregnancy, the antiprogesterone mifepristone facilitates prolactin release. This effect is enhanced by administration of the opioid antagonist naloxone, suggesting an inhibitory-neuromodulatory role of the opioid system. Since hypothalamic dopamine (DA) is the main regulator of prolactin release, in this study we explored the role of DA on prolactin release induced by mifepristone and naloxone treatment. METHODS/RESULTS Rats on day 19 of pregnancy were used. Naloxone treatment did not modify the 3,4-dihydroxyphenylacetic acid/DA (DOPAC/DA) ratio or serum prolactin concentration in control rats. After mifepristone treatment, DA activity diminished significantly without modifying serum prolactin levels. Naloxone administration to antiprogesterone-treated rats did not change the DOPAC/DA ratio but increased serum prolactin. Tyrosine hydroxylase (TH) expression in medial basal hypothalamus (MBH) protein extracts was lowered by pretreatment with mifepristone, with no additional effect of naloxone. While mifepristone decreased the intensity of TH immunoreactivity in the arcuate and periventricular nuclei and in fibers of the median eminence, naloxone treatment had no further effect. CONCLUSIONS (1) A reduction of tuberoinfundibular dopaminergic (TIDA) neuron activity is suggested by the fall of the DOPAC/DA ratio and the low expression of MBH TH; (2) this reduction facilitates prolactin secretion by naloxone, indicating that progesterone stimulates DA neurons to maintain low serum prolactin; (3) naloxone action seems to depend on a previous decrease of DA tone induced by mifepristone, without involve a direct effect on neuronal DA activity, and (4) endogenous opioids may inhibit prolactin secretion through a non-dopaminergic neuronal system that regulates prolactin secretion in which as yet undetermined prolactin-releasing factors may participate.
Collapse
Affiliation(s)
- Marta Soaje
- Laboratorio de Reproducción y Lactancia, IMBECU-CONICET, Mendoza, Argentina.
| | | | | | | | | |
Collapse
|
5
|
Illes P. Modulation of transmitter and hormone release by multiple neuronal opioid receptors. Rev Physiol Biochem Pharmacol 2005; 112:139-233. [PMID: 2573137 DOI: 10.1007/bfb0027497] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
6
|
Soaje M, Bregonzio C, Carón RW, Deis RP. Neurotransmitters involved in the opioid regulation of prolactin secretion at the end of pregnancy in rats. Neuroendocrinology 2004; 80:11-20. [PMID: 15340248 DOI: 10.1159/000080520] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/30/2003] [Accepted: 06/15/2004] [Indexed: 12/22/2022]
Abstract
Using a pharmacological approach, we explored potential mechanisms for the regulation of prolactin secretion by opioid peptides at the end of pregnancy in rats. On day 19 of pregnancy, intracereboventricular administration of the mu-opioid receptor agonist (D-Ala2, NMe-Phe4, Gly-ol5)-enkephalin (DAMGO) or beta-endorphin (beta-END) induced a dose-related increase in serum prolactin levels 30 min later. Pretreatment with the opioid antagonist naloxone abolished the increase induced by DAMGO injection. At lower doses, DAMGO and beta-END did not modify the 3,4-dihydroxyphenylacetic acid/dopamine ratio, but at higher doses, the mu-agonists evoked a significant increase of the dopaminergic activity as compared with saline control. The time course of the effects of beta-END (2.5 microg/rat) showed a higher increase in serum prolactin levels at 15 min than at 30 min after treatment. The 3,4-dihydroxyphenylacetic acid/dopamine ratio increased 15 min after beta-END administration and was even higher 30 min later. Neither the selective kappa-agonist U50,488H nor the selective delta-agonist (D-Pen2, D-Pen5)- enkephalin were able to modify the serum prolactin levels at the doses studied. To evaluate potential neurotransmitters involved in the regulation of prolactin secretion at the end of pregnancy, we combined the administration of serotoninergic or GABAergic antagonists with the opioid agonist DAMGO. The serotonin 5-HT2 receptor antagonist ketanserin increased the serum prolactin levels and potentiated the effect of DAMGO. The intracerebroventricular administration of SR-95531 did not modify the serum prolactin concentration under basal conditions, but partially prevented the increase induced by DAMGO injection. The intracerebroventricular administration of the GABA(B) receptor antagonist phaclofen had no effect on the serum prolactin levels either in naive or DAMGO-treated rats. The present results support the proposal that activation of mu-opioid receptors stimulates prolactin secretion at the end of pregnancy. Although the exact mechanisms by which the opioid system modulates prolactin secretion at the end of pregnancy are unclear, these results suggest an interaction of the opioidergic system with serotoninergic and GABAergic systems, without ruling out a direct or indirect action on dopaminergic neurons. In conclusion, the opioid system may regulate prolactin secretion at the end of pregnancy through either stimulatory (present results) or inhibitory actions previously described.
Collapse
Affiliation(s)
- Marta Soaje
- Laboratorio de Reproducción y Lactancia, IMBECU-CONICET, Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza, Argentina.
| | | | | | | |
Collapse
|
7
|
Ko MCH, Willmont KJ, Lee H, Flory GS, Woods JH. Ultra-long antagonism of kappa opioid agonist-induced diuresis by intracisternal nor-binaltorphimine in monkeys. Brain Res 2003; 982:38-44. [PMID: 12915238 PMCID: PMC2863110 DOI: 10.1016/s0006-8993(03)02938-x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Kappa opioid receptor (KOR) agonists such as U-50488H and bremazocine are analgesics and diuretics. In monkeys, the selective KOR antagonist, nor-binaltorphimine (nor-BNI), produces a long-lasting antagonism of the antinociceptive effects of U-50488H but not those of bremazocine, suggesting that KOR-mediated antinociception may occur through two distinct KORs. The aim of this study was to characterize the antagonist effect of nor-BNI against the diuretic effects of U-50488H and bremazocine in monkeys. Urine outputs were collected over 3 h subsequent to i.m. administration of KOR agonists. Both U-50488H (0.032-1 mg/kg) and bremazocine (0.00032-0.01 mg/kg) dose-dependently increased urine output and the diuretic effect reached a plateau at higher doses. The maximum effect of either U-50488H or bremazocine was approximately 15 ml/kg/3 h of urine. Pretreatment with intracisternal nor-BNI 0.32 mg significantly blocked both U-50488H (0.18 mg/kg)- and bremazocine (0.0032 mg/kg)-induced diuresis for 20 weeks. However, the same dose of nor-BNI 0.32 mg given subcutaneously was not effective. These results demonstrate that central KOR mediate KOR agonist-induced diuresis in monkeys. More important, this study provides functional evidence for a homogenous population of KOR underlying KOR-mediated diuresis and illustrates a unique pharmacological profile of nor-BNI-induced ultra-long KOR antagonism in vivo.
Collapse
Affiliation(s)
- M C H Ko
- Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
| | | | | | | | | |
Collapse
|
8
|
Andrews ZB, Grattan DR. Opioid receptor subtypes involved in the regulation of prolactin secretion during pregnancy and lactation. J Neuroendocrinol 2003; 15:227-36. [PMID: 12588510 DOI: 10.1046/j.1365-2826.2003.00975.x] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Afferent endogenous opioid neuronal systems facilitate prolactin secretion in a number of physiological conditions including pregnancy and lactation, by decreasing tuberoinfundibular dopamine (TIDA) inhibitory tone. The aim of this study was to investigate the opioid receptor subtypes involved in regulating TIDA neuronal activity and therefore facilitating prolactin secretion during early pregnancy, late pregnancy and lactation in rats. Selective opioid receptor antagonists nor-binaltorphimine (kappa-receptor antagonist, 15 micro g/5 micro l), beta funaltrexamine (mu-receptor antagonist, 5 microg/5 microl) and naltrindole (delta-receptor antagonist, 5 microg/5 microl) or saline were administered intracerebroventricularly (i.c.v.) on day 8 of pregnancy during a nocturnal prolactin surge, on day 21 of pregnancy during the ante partum prolactin surge or on day 7 of lactation before the onset of a suckling stimulus. Serial blood samples were collected at regular time intervals, via chronic indwelling jugular cannulae, before and after drug administration and plasma prolactin was determined by radioimmunoassay. TIDA neuronal activity was measured using the 3,4-dihydroxyphenylacetic acid (DOPAC) : dopamine ratio in the median eminence 2 h 30 min after i.c.v. drug injection. In each experimental condition, plasma prolactin was significantly inhibited by both kappa- and mu-receptor antagonists, whereas the delta-receptor antagonist had no effect compared to saline-injected controls. Similarly, nor-binaltorphimine and beta funaltrexamine significantly increased the median eminence DOPAC : dopamine ratio during early and late pregnancy, and lactation whereas naltrindole had no effect compared to saline-injected controls. These data suggest that TIDA neuronal activity, and subsequent prolactin secretion, is regulated by endogenous opioid peptides acting at both kappa- and mu-opioid receptors during prolactin surges of early pregnancy, late pregnancy and lactation.
Collapse
MESH Headings
- Animals
- Female
- Injections, Intraventricular
- Lactation/metabolism
- Naltrexone/analogs & derivatives
- Naltrexone/pharmacology
- Narcotic Antagonists/pharmacology
- Pituitary Gland/metabolism
- Pregnancy
- Pregnancy, Animal/metabolism
- Prolactin/blood
- Prolactin/metabolism
- Rats
- Rats, Sprague-Dawley
- Receptors, Opioid/metabolism
- Receptors, Opioid, delta/antagonists & inhibitors
- Receptors, Opioid, delta/metabolism
- Receptors, Opioid, kappa/antagonists & inhibitors
- Receptors, Opioid, kappa/metabolism
- Receptors, Opioid, mu/antagonists & inhibitors
- Receptors, Opioid, mu/metabolism
Collapse
Affiliation(s)
- Z B Andrews
- Department of Anatomy and Structural Biology and Neuroscience Research Centre, School of Medical Sciences, University of Otago, Dunedin, New Zealand
| | | |
Collapse
|
9
|
Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000; 80:1523-631. [PMID: 11015620 DOI: 10.1152/physrev.2000.80.4.1523] [Citation(s) in RCA: 1490] [Impact Index Per Article: 62.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Prolactin is a protein hormone of the anterior pituitary gland that was originally named for its ability to promote lactation in response to the suckling stimulus of hungry young mammals. We now know that prolactin is not as simple as originally described. Indeed, chemically, prolactin appears in a multiplicity of posttranslational forms ranging from size variants to chemical modifications such as phosphorylation or glycosylation. It is not only synthesized in the pituitary gland, as originally described, but also within the central nervous system, the immune system, the uterus and its associated tissues of conception, and even the mammary gland itself. Moreover, its biological actions are not limited solely to reproduction because it has been shown to control a variety of behaviors and even play a role in homeostasis. Prolactin-releasing stimuli not only include the nursing stimulus, but light, audition, olfaction, and stress can serve a stimulatory role. Finally, although it is well known that dopamine of hypothalamic origin provides inhibitory control over the secretion of prolactin, other factors within the brain, pituitary gland, and peripheral organs have been shown to inhibit or stimulate prolactin secretion as well. It is the purpose of this review to provide a comprehensive survey of our current understanding of prolactin's function and its regulation and to expose some of the controversies still existing.
Collapse
Affiliation(s)
- M E Freeman
- Department of Biological Science, Florida State University, Tallahassee, Florida 32306-4340, USA.
| | | | | | | |
Collapse
|
10
|
Soaje M, Deis RP. Participation of the opioid system in the regulation of prolactin secretion in androgenized rats: effect of ovarian steroids. Eur J Pharmacol 1999; 371:43-9. [PMID: 10355593 DOI: 10.1016/s0014-2999(99)00152-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
We examined the role of the opioid system on the regulation of prolactin secretion in neonatally androgenized rats and evaluated the participation of ovarian steroids in this regulation. Androgenized rats exhibited an increase of prolactin secretion with higher serum circulating levels in the afternoon (1800) than in the morning (1000). The administration of the opioid antagonist naloxone (2 mg/kg, 30 min before decapitation) reduced serum prolactin levels in both groups. To identify the opioid receptor subtypes involved in this regulation, opioid agonists were administered i.c.v. 15 min before the decapitation (1000). The mu-opioid receptor agonist DAMGO ([D-Ala2, NMe-Phe4, Gly5-ol]-enkephalin) caused a significant increase in serum prolactin concentration. The selective kappa-opioid receptor agonist U-50, 488H (trans-(+/-)-3,4-dichloro-N-[2(1-pyrrolidinyl)-cyclohexyl]-benzene acetamide methane sulfonate salt) induced a small but significant increase in serum prolactin levels but no effect was observed after administration of the delta-opioid agonist DPDPE ([D-Pen2, D-Pen5]-enkephalin). The role of oestradiol and the opioid system in the continuous secretion of prolactin was also study. Chronic gonadectomy (3-4 weeks) reduced serum prolactin concentrations measured at 1000 but the administration of naloxone had no effect. Three days of oestrogen treatment (2 microg/rat in oil) restored serum prolactin levels compared with ovariectomized animals and this effect was abolished by naloxone treatment. Interestingly, acute ovariectomy or administration of tamoxifen to intact androgenized rats did not prevent the continuous secretion of prolactin observed in these animals and naloxone treatment reduced serum prolactin levels in both groups of rats. We also examine the participation of adrenal progesterone and the endogenous opioid peptides on the regulation of prolactin levels in androgenized rats. After adrenalectomy, no changes in serum prolactin levels (1000) were observed compared with the control animal and naloxone treatment significantly reduced circulating prolactin levels. Progesterone treatment to intact androgenized rats significantly increased prolactin levels and the administration of naloxone blocked the stimulatory effect of the steroid. These results suggest that the opioid system play a role in the regulation of prolactin secretion in androgenized rats modulated by the persistence of oestrogen action. Moreover, the presence or absence of progesterone did not modify the regulation of prolactin secretion by the opioids. The mu- and kappa-opioid receptor subtypes are the ones involved in the modulation of pituitary prolactin secretion.
Collapse
Affiliation(s)
- M Soaje
- Laboratorio de Reproducción y Lactancia, CRICYT-CONICET, Mendoza, Argentina.
| | | |
Collapse
|
11
|
Shieh KR, Pan JT. Nicotinic control of tuberoinfundibular dopaminergic neuron activity and prolactin secretion: diurnal rhythm and involvement of endogenous opioidergic system. Brain Res 1997; 756:266-72. [PMID: 9187341 DOI: 10.1016/s0006-8993(97)00157-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The possible involvement of cholinergic and opioidergic neurons in the control of diurnal changes of tuberoinfundibular dopaminergic (TIDA) neuronal activity was reported. Adult Sprague-Dawley rats ovariectomized and treated with estrogen were used. All drugs were administered centrally through preimplanted intracerebroventricular cannula, and both TIDA neuronal activity and serum prolactin level were determined. Nicotine (10 ng/3 microl/rat) given at 10:00 h significantly inhibited TIDA neuronal activity from 5 to 30 min and stimulated serum PRL levels at 5 and 15 min. Co-administration of either mecamylamine (1 microg) or naloxone (2.5 microg) prevented both nicotine's effects. A dose-related (0.1-100 ng) effect of nicotine on TIDA neuronal activity and serum PRL level was also observed in the morning when TIDA neuronal activity is high and serum PRL level is low, but not in the afternoon when the former activity is low and the latter is high. When atropine (20 microg), naloxone (25 microg) or Nor-BNI (20 microg) was given at 14:00 h all increased the lowered TIDA neuronal activity in the afternoon. When atropine was co-administered with either naloxone or Nor-BNI, however, no additive effect was observed. Submaximal doses of atropine (0.2 microg), mecamylamine (0.1 microg) or naloxone (0.25 microg) was also effective in stimulating the afternoon levels of TIDA neuronal activity and inhibiting serum PRL, and no additive effect was observed either. Moreover, simultaneous injection of morphine (15 microg) prevented atropine's effect in the afternoon. These results indicate that cholinergic neurons may act through activating the endogenous opioidergic neurons to exhibit an inhibitory effect on TIDA neuronal activity and a stimulatory one on prolactin secretion. A diurnal difference in its endogenous activity between morning and afternoon was also implicated.
Collapse
Affiliation(s)
- K R Shieh
- Department of Physiology, Schools of Life Science and Medicine, National Yang-Ming University, Taipei, Taiwan, ROC
| | | |
Collapse
|
12
|
Yamada M, Groshan K, Phung CT, Yamada M, Hisamitsu T, Richelson E. The expression of mRNA for a kappa opioid receptor in the substantia nigra of Parkinson's disease brain. BRAIN RESEARCH. MOLECULAR BRAIN RESEARCH 1997; 44:12-20. [PMID: 9030693 DOI: 10.1016/s0169-328x(96)00139-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
We molecularly cloned the kappa opioid receptor from a human substantia nigra cDNA library. When expressed in HEK293 cells, the cloned receptor had similar pharmacological characteristics to the rat kappa opioid receptor. Northern blot analysis showed the presence of a single transcript of about 6 kb in size for mRNA prepared from the substantia nigra. Using in situ hybridization histochemistry, we studied the expression of this receptor in postmortem human brains from control and Parkinson's disease subjects. Kappa opioid receptor mRNA was present in melanized (possibly dopaminergic) neurons of the substantia nigra and the nucleus paranigralis. On the other hand, Parkinson's disease brains had markedly fewer melanized neurons, as expected, and correspondingly very low or background levels of mRNA for the kappa opioid receptor. However, in some cases, remaining melanized neurons still expressed the receptor mRNA. From these results we suggest that dopaminergic neurons in the human substantia nigra and the nucleus paranigralis synthesize kappa opioid receptors and express them in their perikarya and their terminal regions. The kappa opioid receptor expressed in the melanized neurons may play a role in the normal function of dopaminergic systems and possibly in the etiology of Parkinson's disease.
Collapse
Affiliation(s)
- M Yamada
- Department of Psychiatry, Mayo Foundation and Mayo Clinic Jacksonville, FL 32224, USA
| | | | | | | | | | | |
Collapse
|
13
|
Ali SF, Newport GD, Slikker W, Rothman RB, Baumann MH. Neuroendocrine and neurochemical effects of acute ibogaine administration: a time course evaluation. Brain Res 1996; 737:215-20. [PMID: 8930368 DOI: 10.1016/0006-8993(96)00734-2] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Ibogaine (IBO) is an indole alkaloid that is reported to facilitate drug abstinence in substance abusers. Despite considerable investigation, the mechanism of IBO action in vivo and its suitability as a treatment for drug addiction remains unclear. The present study was designed to evaluate the time-course effects of acute IBO on neuroendocrine and neurochemical indices. Adult male rats were treated with i.p. saline or 50 mg/kg IBO and sacrificed 15, 30, 60, 120 min and 24 h later. Trunk blood was collected for hormone measures and brains were dissected for neurochemical analyses. IBO produced a rapid elevation in plasma prolactin that declined to control levels by 60 min. Corticosterone levels increased 15 min after drug administration, continued to increase for 120 min, but returned to control levels 24 h after dosing. IBO decreased dopamine (DA) concentrations in the striatum and frontal cortex at 30, 60 and 120 min after injection while DA metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), were elevated over the same time period. 24 h after IBO, DOPAC concentrations in striatum and HVA levels in the frontal cortex were below control values. Serotonin (5-HT) and its metabolite 5-hydroxyindole acetic acid (5-HIAA) were decreased at 60 min after IBO administration only in the striatum. These data indicate that a single injection of IBO produces a spectrum of effects that includes: (1) elevation of plasma prolactin and corticosterone, (2) short- and long-term effects on DA neurotransmission, and (3) modest, transient effects of 5-HT neurotransmission. The effects of IBO reported herein may have relevance to the anti-addictive properties of this drug, and this proposal warrants further investigation.
Collapse
Affiliation(s)
- S F Ali
- Neurochemistry Laboratory, National Center for Toxicological Research, FDA, Jefferson, AR 72079-9502, USA
| | | | | | | | | |
Collapse
|
14
|
Marotti T, Gabrilovac J, Rabatic S, Smejkal-Jagar L, Rocic B, Haberstock H. Met-enkephalin modulates stress-induced alterations of the immune response in mice. Pharmacol Biochem Behav 1996; 54:277-84. [PMID: 8728569 DOI: 10.1016/0091-3057(95)02112-4] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Overnight restraint stress of mice decreased ConA-driven lymphocyte proliferation, plaque-forming cell response to sheep red blood cells (SRBC), and NK activity in the spleen, but the phagocytic activity was enhanced. Injection of methionine-enkephalin (MENK), 10 mg/kg, i.p., 30 min before restraint, abolished these changes (except for the NK activity) and attenuated the stress-induced elevation of glucocorticoids. However, MENK itself affected the immune responses like stress: It decreased NK activity and the PFC response and enhanced phagocytic activity. Contrary to results with stress, MENK had no effect on cell proliferation. The opioid-receptor antagonist naloxone given before restraint reversed the stress-induced enhancement of phagocytosis and the decrease of T-cell proliferation. Alterations of the immune responses induced by restraint stress seem to be mediated by at least two mechanisms: activation of the hypothalamus-pituitary-adrenal (HPA) axis and the secretion of opioid peptides. MENK injected before stress may interfere with either or both mechanisms. T or B lymphocytes seem to be affected by the activation of the HPA axis, and phagocytes by a direct opioid action, whereas NK cells seem to be under the influence of another control mechanism.
Collapse
Affiliation(s)
- T Marotti
- Department of Experimental Biology and Medicine, Rudjer Boskovic Institute, Zagreb, Croatia
| | | | | | | | | | | |
Collapse
|
15
|
Mansour A, Burke S, Pavlic RJ, Akil H, Watson SJ. Immunohistochemical localization of the cloned kappa 1 receptor in the rat CNS and pituitary. Neuroscience 1996; 71:671-90. [PMID: 8867040 DOI: 10.1016/0306-4522(95)00464-5] [Citation(s) in RCA: 130] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Several lines of evidence have demonstrated the presence of three opioid receptor types in the CNS and periphery. These receptors are referred to as mu, delta and kappa, and have been implicated in a wide variety of functions. The present study examines the localization of the kappa 1 receptor, a region of the receptor that has little homology with mu and delta receptors. Immunohistochemical studies in Zamboni-fixed rat tissue demonstrate immunoreactive perikarya and/or fibers in such regions as the deep layers of the parietal, temporal and occipital cortex, parasubiculum, central and medial amygdala, bed nucleus stria terminalis, nucleus accumbens, olfactory tubercle, endopiriform nucleus, claustrum, hypothalamic nuclei, median eminence, midline thalamic nuclei, zona incerta, central gray, caudal linear and dorsal raphe, substantia nigra, pars reticulata, ventral tegmental area, parabrachial nucleus, spinal trigeminal nucleus, nucleus of the solitary tract, spinal cord and the dorsal root ganglia. Specific kappa 1 receptor-like immunohistochemical staining is also observed in the pituitary, where immunoreactive perikarya and fibers are localized in the neural and intermediate lobes. Transfection and preabsorption controls suggest that the antibody is selective for the cloned kappa 1 receptor, and does not recognize mu or delta. This immunohistochemical localization corresponds well to previously described kappa 1 receptor mRNA and binding distributions and provides new insights into the cellular localization and pre- and postsynaptic organization of the kappa 1 receptor-like proteins in the rat brain and pituitary. The functional implications of these results are discussed in light of the kappa 1 receptors play in hormonal regulation, antinociception and reward.
Collapse
Affiliation(s)
- A Mansour
- Mental Health Research Institute, University of Michigan, Ann Arbor, USA
| | | | | | | | | |
Collapse
|
16
|
Hashiguchi Y, Molina PE, Fan J, Lang CH, Abumrad NN. Central opiate modulation of growth hormone and insulin-like growth factor-I. Brain Res Bull 1996; 40:99-104. [PMID: 8724426 DOI: 10.1016/0361-9230(96)00045-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The effects of central administration of morphine-sulfate (MOR:80 micrograms) and morphine-6-glucuronide (M6G:1 microgram) on the growth hormone (GH)/insulin-like growth factor (IGF) system were assessed. MOR and M6G were injected intracerebroventricularly (ICV) in chronically catheterized 24 h fasted rats; time-matched control animals received H2O (5 microliters). MOR increased plasma GH concentrations 3-fold 2 h after i.c.v. injection, and transiently increased the plasma concentration and liver content of IGF-I (60% and 90%, respectively) 30 min after i.c.v injection. M6G did not produce any significant alterations in plasma GH and IGF-I levels at the time-points measured. Both MOR and M6G increased the concentration of IGF binding protein-1 (IGFBP-1) in plasma and liver 2 h after injection. However, MOR showed 2- to 2.5-fold greater effect than M6G in stimulating plasma and liver IGFBP-1. MOR and M6G produced similar increases in plasma epinephrine (5-fold), norepinephrine (3-fold) and corticosterone (1.5-fold). Neither opiate significantly altered circulating insulin levels. These findings suggest that opiate modulation of GH and IGF may be hormone-independent and centrally modulated. We speculate that differential affinities of MOR and M6G to the different opiate receptor subtypes might be responsible for their distinct effects on GH/IGF-I system.
Collapse
Affiliation(s)
- Y Hashiguchi
- Department of Surgery, SUNY at Stony Brook 11794-8191, USA
| | | | | | | | | |
Collapse
|
17
|
Lai Z, Zhai Q, Liu Z, Roos P, Nyberg F. Morphine-induced prolactin release precedes a down-regulation of prolactin receptors in the male rat choroid plexus and hypothalamus. Neurosci Res 1995; 23:313-6. [PMID: 8545080 DOI: 10.1016/0168-0102(95)00953-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
In previous studies we provided evidence for changes in prolactin (PRL) receptor levels in the male rat brain after continuously infusing morphine using subcutaneously implanted miniosmotic pumps. In this work we have studied the binding of PRL in the male rat brain following morphine administration by both subcutaneous (s.c.) and intracerebroventricular (i.c.v.) injections. The binding in the choroid plexus and the hypothalamus was measured using iodinated ovine PRL (oPRL) as a radiolabel. The results indicated that the density of the PRL-binding sites in the hypothalamus and the choroid plexus were significantly decreased 4 h and 24 h after s.c. injections, and also 30 min and 4 h after i.c.v. injections. However, no decrease in PRL-binding was observed 15 min after i.c.v. injection of morphine. The plasma levels of PRL were measured by radioimmunoassay (RIA) and were found to be significantly increased after 30 min and 4 h in all treated animals. Following i.c.v. injection a significant increase in plasma PRL was observed after just 15 min. It was suggested that the down-regulation in PRL binding to some extent at least resulted from receptor overstimulation caused by the morphine-induced elevation in the concentrations of the endogenous hormone.
Collapse
Affiliation(s)
- Z Lai
- Department of Pharmaceutical Biosciences, University of Uppsala, Sweden
| | | | | | | | | |
Collapse
|
18
|
Idänpään-Heikkilä JJ, Rauhala P, Männistö PT. mu- and delta-opioid receptor antisense oligodeoxynucleotides antagonize morphine-induced growth hormone secretion in rats. Eur J Pharmacol 1995; 284:227-30. [PMID: 8549632 DOI: 10.1016/0014-2999(95)00462-t] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Effects of i.c.v. pretreatment with antisense oligodeoxynucleotides (antisense oligos) targeted against either mu- or delta-opioid receptors on morphine-induced release of growth hormone (GH) and prolactin were studied in male rats. The stimulation of GH secretion by i.c.v. morphine was completely inhibited by the antisense oligo targeted against the cloned mu-opioid receptor and significantly reduced by the antisense oligo targeted against the cloned delta-opioid receptor. The antisense oligo targeted against the cloned mu-opioid receptor, but not that targeted against the cloned delta-opioid receptor, abolished the stimulatory effect of acute morphine on prolactin secretion. It is concluded that both the GH and prolactin secretion stimulating effect of morphine is mainly mediated by the cloned mu-opioid receptor. Further, the cloned delta-opioid receptor is involved in the morphine-induced stimulation of GH secretion.
Collapse
MESH Headings
- Analgesics, Opioid/antagonists & inhibitors
- Analgesics, Opioid/pharmacology
- Animals
- Base Sequence
- Cloning, Molecular
- Growth Hormone/metabolism
- Injections, Intraventricular
- Male
- Molecular Sequence Data
- Morphine/antagonists & inhibitors
- Morphine/pharmacology
- Oligonucleotides, Antisense/pharmacology
- Pain Measurement/drug effects
- Prolactin/metabolism
- Rats
- Rats, Wistar
- Receptors, Opioid, delta/drug effects
- Receptors, Opioid, delta/metabolism
- Receptors, Opioid, mu/drug effects
- Receptors, Opioid, mu/metabolism
Collapse
|
19
|
Zhai QZ, Lai Z, Yukhananov R, Roos P, Nyberg F. Decreased binding of growth hormone in the rat hypothalamus and choroid plexus following morphine treatment. Neurosci Lett 1995; 184:82-5. [PMID: 7724051 DOI: 10.1016/0304-3940(94)11174-h] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Male Sprague-Dawley rats were continuously infused with morphine through subcutaneously implanted mini-osmotic pumps over a period of 5 days. The binding of rat growth hormone (rGH) to specific sites in choroid plexus, cortex, hypothalamus, hippocampus and striatum was determined. It was found that in the acute phase of morphine administration the density of growth hormone-binding sites was significantly decreased in choroid plexus and in hypothalamus, but not in any other of the tissues studied. When tolerance to morphine was developed, the level of growth hormone-binding was restored to control level. In the acute phase, the plasma levels of GH, as measured by radioimmunoassay, correlated negatively with the density of the binding sites in choroid plexus and hypothalamus. The decrease in growth hormone-binding in these regions of the rat brain was also confirmed by SDS-polyacrylamide gel electrophoresis of cross-linked complexes of the binding entities to 125I-labelled rGH as visualized by autoradiography. In experiments, where morphine was administrated by intermittent injections, a similar decrease in rGH-binding was observed. However, the time-course of this decrease seemed to be dependent upon the route of administration. Following intracerebroventricular (i.c.v.) injections, the binding of the hormone was already affected after 30 min, whereas the binding of rGH in brain areas after subcutaneous (s.c.) injections was affected at a later stage.
Collapse
Affiliation(s)
- Q Z Zhai
- Department of Pharmaceutical Bioscience, University of Uppsala, Sweden
| | | | | | | | | |
Collapse
|
20
|
Lin JY, Pan JT. Effects of endogenous opioid peptides and their analogs on the activities of hypothalamic arcuate neurons in brain slices from diestrous and ovariectomized rats. Brain Res Bull 1995; 36:225-33. [PMID: 7697375 DOI: 10.1016/0361-9230(95)91085-m] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Various endogenous opioid peptides and some of their analogs were used in this study to test their effects on the membrane activities of hypothalamic arcuate neurons in brain slices. Both ovariectomized and diestrous rats were used in the study, and freshly prepared brain slices from these animals were used for extracellular single-unit recording studies. All of the opioids exhibited potent inhibitory effects on the firing of arcuate neurons, viz., beta-endorphin inhibited 55% (n = 33), DAGO 62% (n = 21), dynorphin A 55% (n = 11), U50,488 36% (n = 39), Met-enkephalin 35% (n = 54), and DPDPE 50% (n = 8) of tested arcuate neurons from ovariectomized rats. Significantly higher percentage of inhibition was observed in slice preparations from diestrous rats for DAGO 86% (n = 22), and slightly higher for dynorphin A 59% (n = 22) and U50,488 53% (n = 15). Pretreatment with naloxone prevented most of the actions by beta-endorphin and DAGO, and nor-binaltorphimine prevented those by dynorphin A and U50,488. Most of the effects of Met-enkephalin could also be blocked by nor-binaltorphimine (67%, n = 6), but less by naltrindole (25%, n = 8). Naltrindole, however, seemed to be more effective in blocking the action of [D-Pen2,5]-enkephalin (100%, n = 2). In summary, all opioids tested exerted potent inhibitory effects upon the firing of arcuate neurons possibly through multiple opioid receptors, and the presence of ovarian hormones may have an effect on the neuron's responsiveness to opioid acting on mu type receptors.
Collapse
Affiliation(s)
- J Y Lin
- Institute of Physiology, National Yang-Ming Medical College, Taipei, Taiwan, Republic of China
| | | |
Collapse
|
21
|
Abstract
Classification of drugs acting on the kappa-opioid receptors seems to be difficult, since some of these ligands are also sigma agonists and/or display non-opioid actions as well. Furthermore, certain benzomorphans having kappa-agonistic character, are shown to be mu-antagonists too. Therefore the classification of the kappa-opioid receptor has to be presently restricted to two subclasses that also have physiological meaning. Dynorphin and Met-enkephalin-Arg6-Phe7 are proposed as endogenous peptide ligands for kappa-receptors. Nonpeptide agonists are benzeneacetamides interacting with the kappa1 receptor. Benzomorphans bind to both subtypes of kappa-receptors. No selective nonpeptide ligand for the kappa2 receptor exists as yet. Nor-binaltorphimine, a specific kappa-antagonist also inhibits both kappa-subtypes. Further research for kappa2 selective drugs is necessary for clear distinction between the two kappa-opioid binding sites. Molecular cloning of opioid receptors including their subtypes are expected to provide direct proof of their existence.
Collapse
Affiliation(s)
- M Wollemann
- Institute of Biochemistry, Hungarian Academy of Sciences, Szeged
| | | | | |
Collapse
|
22
|
Manzanares J, Wagner EJ, Moore KE, Lookingland KJ. Kappa opioid receptor-mediated regulation of prolactin and alpha-melanocyte-stimulating hormone secretion in male and female rats. Life Sci 1993; 53:795-801. [PMID: 8394964 DOI: 10.1016/0024-3205(93)90501-s] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
The purpose of this study was to examine the effects of the kappa opioid receptor agonist U-50,488 and antagonist nor-binaltorphimine (NOR-BNI) on the secretion of prolactin and alpha-melanocyte-stimulating hormone (alpha MSH) in male and female rats. Activation of kappa opioid receptors with U-50,488 increased plasma prolactin concentrations in both male and female rats, whereas blockade of kappa opioid receptors with NOR-BNI decreased plasma prolactin concentrations in male, but not in female rats. U-50,488 also increased and NOR-BNI decreased plasma concentrations of alpha MSH; similar effects were observed in both male and female rats. These results reveal a sexual difference in kappa opioid receptor-mediated regulation of prolactin, but not alpha MSH secretion.
Collapse
Affiliation(s)
- J Manzanares
- Department of Pharmacology and Toxicology, Michigan State University, East Lansing 48824
| | | | | | | |
Collapse
|
23
|
Simpkins JW, Millard WJ, Berglund LA. Effects of chronic stimulation or antagonism of opiate receptors on GH secretion in male and female rats. Life Sci 1993; 52:1443-50. [PMID: 8385257 DOI: 10.1016/0024-3205(93)90068-e] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
The present study was undertaken to assess the role of endogenous opioid systems in the sexually dimorphic pattern of growth hormone (GH) secretion. To this end, male rats were treated chronically (6 to 12 h) with morphine and estrogen-exposed, ovariectomized female rats with morphine or naloxone. Chronic morphine exposure of male rats caused a 12-fold increase in basal GH levels and a modest rise in GH pulse frequency. These two changes resulted in a 3-fold increase in both mean GH concentration and total GH secretion over 6 h. In female rats, chronic morphine reduced GH pulse amplitudes but did not significantly affect other parameters of GH secretion. By contrast, chronic naloxone treatment of female rats reduced basal GH levels by 64% without affecting GH pulse amplitudes or pulse frequency. These data suggest that endogenous opioid systems are involved in the regulation of the basal GH secretion in both male and female rats.
Collapse
Affiliation(s)
- J W Simpkins
- Department of Pharmacodynamics, University of Florida, Gainesville 32610
| | | | | |
Collapse
|
24
|
Beauvillain JC, Moyse E, Dutriez I, Mitchell V, Poulain P, Mazzuca M. Localization of mu opioid receptors on the membranes of nerve endings and tanycytes in the guinea-pig median eminence by electron microscopic radioautography. Neuroscience 1992; 49:925-36. [PMID: 1331859 DOI: 10.1016/0306-4522(92)90368-c] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The high density of opioid-containing nerve endings in the median eminence together with the absence of direct effects of opioids upon pituitary suggest a local action of opioids in the median eminence. The aim of this work was to address the occurrence of mu-opioid binding sites in the median eminence at the electron microscopic level, using the highly selective radioligand [125I]FK 33-824. mu-Opioid receptors were labeled in vitro on slightly prefixed slices of mediobasal hypothalamus. The labeling was essentially detected in the external part of the median eminence. Most of the silver grains overlaid membrane appositions. Two overall types of appositions were concerned: nerve terminal-nerve terminal or nerve terminal-tanycyte. Detailed analysis of the silver grain distribution indicated that mu receptors were observed on membranes of different types of nerve endings but also of tanycytes. All the binding sites were localized out of synaptic junctions since the median eminence is totally devoid of these structures. Our results suggest that in the median eminence, opioid peptides have a paracrine and/or autocrine action occurring at least via mu receptors located on nerve terminals but also on tanycytes.
Collapse
|
25
|
Baumann MH, Rabii J. Inhibition of suckling-induced prolactin release by mu- and kappa-opioid antagonists. Brain Res 1991; 567:224-30. [PMID: 1667901 DOI: 10.1016/0006-8993(91)90799-2] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Evidence suggests that endogenous opioid peptides (EOP) are involved in the hyperprolactinemia and suppression of luteinizing hormone (LH) release associated with lactation. To address this hypothesis, we investigated the effects of various opioid receptor antagonists on suckling-induced prolactin (PRL) and LH responses in primiparous, lactating rats. All animals were fitted with indwelling jugular catheters to allow serial blood sampling, and some rats received intracerebroventricular (i.c.v.) cannulae for central drug injection. Naloxone (2.0 mg/kg, i.v.) was employed as a broad spectrum opioid antagonist, whereas beta-funaltrexamine (beta-FNA, 1.0-5.0 micrograms, i.c.v.), naloxonazine (NAZ, 20 mg/kg, i.v.) and nor-binaltorphimine (nor-BNI, 4.0-16.0 micrograms, i.c.v.) were used to block mu, mu 1 and kappa receptor sites, respectively. In vehicle-treated rats, pup suckling evoked a dramatic increase in plasma PRL and a concurrent decrease in circulating LH. Naloxone caused a modest, though significant, attenuation of the PRL surge during nursing. beta-FNA and nor-BNI inhibited suckling-induced PRL release in a dose-related fashion, and at sufficient doses, both antagonists abolished the PRL response. Conversely, the suckling-induced rise in plasma PRL was not affected by NAZ. Naloxone, beta-FNA, and NAZ did not alter the profile of circulating LH in suckled rats, but the highest dose nor-BNI (16 micrograms, i.c.v.) produced a significant elevation in plasma LH. However, even in rats treated with 16.0 micrograms of nor-BNI, plasma LH levels declined in response to the nursing stimulus.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- M H Baumann
- Department of Biological Sciences, Rutgers University, Piscataway, NJ 08855
| | | |
Collapse
|
26
|
Molnár J, Halász B. Mesencephalic sites of action of an enkephalin analogue (D-Met2, Pro5)-enkephalinamide and naloxone on the anterior pituitary of male rats. Brain Res 1991; 563:270-2. [PMID: 1786539 DOI: 10.1016/0006-8993(91)91543-a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
(D-Met2, Pro5)-Enkephalinamide and naloxone injected into the dorsal raphe nucleus affected luteinizing hormone (LH) and prolactin (PRL) release. Drugs given into the reticular tegmental nucleus and dorsal part of the periaqueductal gray matter induced a PRL response and their administration into the central superior midbrain raphe nucleus caused changes in growth hormone (GH) secretion. The inferior colliculus and the lateral part of the periaqueductal gray matter were ineffective sites.
Collapse
Affiliation(s)
- J Molnár
- Second Department of Anatomy, Semmelweis University of Medicine, Budapest, Hungary
| | | |
Collapse
|
27
|
Kapoor R, Willoughby JO. Activation of mu opioid receptors in the pre-optic-anterior hypothalamus releases prolactin in the conscious male rat. Neuropeptides 1991; 19:231-6. [PMID: 1681455 DOI: 10.1016/0143-4179(91)90089-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Microinjection of opioid agonists into the pre-optic-anterior hypothalamus (PO/AHA) was used to determine the identity of the opioid receptor subtype(s) involved in the stimulation of prolactin release. The mu agonist DAGO [(D-Ala2, NMe-Phe4, Gly-o15)-enkephalin] was the only opioid agonist to show dose-dependent release of prolactin, the lowest significant dose being 0.001 nmoles. Neither the specific delta agonist DPDPE [(D-Pen2, D-Pen5)-enkephalin] nor the specific kappa agonist U50,488H [(trans-3,4-dichloro-N-methyl-N-(2-(1-pyrrodinyl)-cyclohexyl)-benz ene acetamide] showed dose-dependent increase of prolactin secretion, or indeed any significant increase in prolactin secretion in the dose range 0.01-1 nmoles and 0.01-10 nmoles respectively. We suggest that mu (and not kappa or delta) opioid receptors in the PO/AHA are involved in the opioid stimulated release of prolactin in the conscious male rat.
Collapse
MESH Headings
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer
- Animals
- Anterior Hypothalamic Nucleus/drug effects
- Anterior Hypothalamic Nucleus/metabolism
- Dose-Response Relationship, Drug
- Dynorphins/pharmacology
- Enkephalin, Ala(2)-MePhe(4)-Gly(5)-
- Enkephalin, D-Penicillamine (2,5)-
- Enkephalin, Leucine-2-Alanine/pharmacology
- Enkephalins/pharmacology
- Male
- Preoptic Area/drug effects
- Preoptic Area/metabolism
- Prolactin/metabolism
- Pyrrolidines/pharmacology
- Rats
- Receptors, Opioid/metabolism
- Receptors, Opioid, mu
Collapse
Affiliation(s)
- R Kapoor
- Centre for Neuroscience, Flinders Medical Centre, South Australia
| | | |
Collapse
|
28
|
Willoughby JO, Kapoor R, Mackenzie L. Intrahypothalamic Mu-, not Delta- or Kappa-Opioid Receptor Activation Causes Growth Hormone Secretion. J Neuroendocrinol 1991; 3:149-54. [PMID: 19215516 DOI: 10.1111/j.1365-2826.1991.tb00257.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Abstract The possible effects of opioid receptor agonists on growth hormone (GH)-releasing factor or somatostatin neurons were examined by measuring the effects of localized intracerebral injections of mu-, delta- and kappa-selective agonists on GH secretion. Serial GH concentrations were measured in plasma in unanaesthetized male rats chronically prepared with venous and intracerebral cannulae, before and after treatment with bilateral intracerebral injections of opioid agonists in the preoptic anterior hypothalamic area and medial basal hypothalamus. In the medial basal hypothalamus, injections of the mu-agonist DAGO (Tyr-D-Ala-Gly-(Me)Phe-Gly-ol) caused dose-responsive increases in GH, the maximally effective dose being 0.001 nmoles. Injection of 10,000-fold higher doses of the delta-agonist DPDPE ([D-Pen, D-Pen]enkephalin) and the kappa-agonist U50,488H were also effective in stimulating GH secretion. In the preoptic anterior hypothalamic area, DAGO caused dose-responsive increases in GH, the maximally effective dose being 0.01 nmoles. U50.488H was ineffective at 1,000-fold higher doses while DPDPE was effective at 100- to 1,000-fold higher doses. We conclude that hypothalamic mu-opioid receptor activation on or near somatostatin or GH-releasing factor neurons causes GH secretion. Opioids capable of acting on other opioid receptors may also stimulate GH secretion, though only at doses that seem likely to affect mu-receptors.
Collapse
Affiliation(s)
- J O Willoughby
- Centre for Neuroscience and Department of Medicine, Flinders Medical Centre, Bedford Park, South Australia 5042
| | | | | |
Collapse
|
29
|
Hein PR, Schatorjé JS, Frencken HJ, Segers MF, Thomas CM. The effect of chronic oral methadone treatment on monkey chorionic gonadotropin, estradiol, dehydroepiandrosterone sulfate, progesterone, prolactin and cortisol levels during pregnancy in the cynomolgus monkey (Macaca fascicularis). Eur J Obstet Gynecol Reprod Biol 1991; 38:145-50. [PMID: 1825302 DOI: 10.1016/0028-2243(91)90192-n] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The effect of chronic methadone treatment upon the serum levels of Estradiol (E2), Progesterone (P), Prolactin (Prl), monkey chorionic gonadotropin (mCG), dehydroepiandrosterone sulfate (DHEAS) and Cortisol (C) in pregnant Cynomolgus monkeys (Macaca fascicularis) is described in comparison with the hormone levels in a control group. Only DHEAS was significantly decreased in late pregnancy in the methadone group. From these data it can not be concluded that methadone treatment compromises (feto)placental function. The observed intra-uterine growth retardation in the methadone treated group might be a result of a direct influence of methadone upon growth.
Collapse
Affiliation(s)
- P R Hein
- Department of Obstetrics and Gynecology, University Hospital Nijmegen, The Netherlands
| | | | | | | | | |
Collapse
|
30
|
|
31
|
Maggi R, Limonta P, Dondi D, Piva F. Modulation of the binding characteristics of hypothalamic mu opioid receptors in rats by gonadal steroids. J Steroid Biochem Mol Biol 1991; 40:113-21. [PMID: 1659872 DOI: 10.1016/0960-0760(91)90174-4] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Recent evidence suggests that the effects of the opioids on gonadotropin release may depend on the endocrine status existing in the experimental animal. In the brain, the effects of the opioids are exerted through the interaction with different classes of opioid receptors (mu, delta, kappa, etc.). Among these, the mu receptors appear to be particularly relevant to the control of gonadotropin secretion. Different groups of experiments have been performed in the rat in order to analyze whether changes of circulating levels of sex steroids may have an impact on the binding characteristics of hypothalamic mu opioid receptors, as evaluated by a receptor binding assay performed on plasma membrane preparations, using [3H]dihydromorphine as a mu ligand. In a first series of experiments, it has been observed that the ontogenesis of hypothalamic mu opioid receptors is different in male and in female rats: the concentration of mu sites, similar in animals of the two sexes at 16 days of age, increases in females, but not in males, between day 16 and day 26 of life. This sexual difference persists in 60-day old animals, when the brain is fully mature. It has also been observed that the pattern of maturation of hypothalamic mu receptors can be reversed by neonatal castration of males and by neonatal testosterone treatment of females. In a second series of experiments, it has been shown that in the hypothalamus of regularly cycling female rats the concentration of mu receptors varies during the different phases of the estrous cycle. In particular, a rather high density of mu sites during diestrus day 2 and the morning of the day of proestrus was found; this is followed by a progressive decline during the afternoon of the day of proestrus and the day of estrus, with a minimum value of the concentration of mu receptors being recorded in the first day of diestrus. These fluctuations seem to be linked to the physiological changes of serum levels of ovarian steroids: in fact, in a third series of experiments, it has been found that the positive feedback effect on LH release, exerted by the treatment of ovariectomized female rats with estrogens plus progesterone, is accompanied by a significant decrease of the concentration of hypothalamic mu opioid receptors; treatments with estrogens alone, able to induce a negative feedback effect on LH secretion, are not associated with modifications of hypothalamic mu receptors. These data seem to indicate that hypothalamic mu receptors may be involved in the positive but not in the negative feedback control of LH secretion.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- R Maggi
- Department of Endocrinology, University of Milano, Italy
| | | | | | | |
Collapse
|
32
|
Govaerts J, Buydens P, Finné E, Matton A, Vanhaelst L. The growth hormone secretory response to fentanyl in rat: an involvement of mu type receptors. J Endocrinol Invest 1990; 13:911-5. [PMID: 1965314 DOI: 10.1007/bf03349653] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Fentanyl, a selective mu opioid receptor agonist, administered intravenously, influences growth hormone secretion in conscious male rats. A dose-response study demonstrated that the maximum growth hormone release was obtained with 10 micrograms/kg while higher doses were less or not effective. MR-2266 (6 mg/kg i.v.), a mu and kappa opioid receptor antagonist, and bremazocine (0.1 mg/kg i.v.) a mu opioid receptor antagonist with kappa agonistic properties, both potently inhibited the growth hormone response to fentanyl (10 micrograms/kg i.v.). In contrast, the effect of fentanyl on growth hormone release was not blocked in rats treated with either ICI-154129 (30 mg/kg i.v. or 150 micrograms/kg intracerebroventricularly a selective delta opioid receptor antagonist, or U-50488 (10 mg/kg i.v.), a specific kappa opioid receptor agonist. These results suggest that opioid receptors of the mu type are involved in the fentanyl-induced growth hormone release.
Collapse
Affiliation(s)
- J Govaerts
- Laboratory of Pharmacology, Faculty of Medicine and Pharmacy, Free University of Brussels (V.U.B.), Belgium
| | | | | | | | | |
Collapse
|
33
|
Molnár J, Marton J, Halász B. Central nervous system sites of action of an enkephalin analogue, (d-met, pro)-enkephalinamide, and naloxone on the secretion of five anterior pituitary hormones of male rats. J Neuroendocrinol 1990; 2:477-83. [PMID: 19215377 DOI: 10.1111/j.1365-2826.1990.tb00436.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Abstract Central nervous system sites of action of opioid peptides on pituitary hormone secretion were investigated. One nmol of an enkephalin analogue, (D-Met(2), Pro(5))-enkephalinamide, and 10 nmol of the opiate antagonist naloxone were injected into ten different regions of the brain of conscious male rats and their effect on the release of five anterior pituitary hormones tested. The injections were made through a special injection cannula which was inserted into the brain through a guide cannula fixed on the skull and implanted into the brain 5 to 7 days earlier. Both compounds injected into the medial septum, medial preoptic area and hypothalamic paraventricular nucleus affected prolactin, growth hormone and luteinizing hormone (LH) secretion. The enkephalin analogue stimulated prolactin and growth hormone and inhibited LH release. Naloxone induced the opposite effect. Drugs given into the hypothalamic ventromedial nucleus caused changes in plasma prolactin and growth hormone levels. Enkephalinamide increased and naloxone decreased plasma concentrations of both hormones. Administration of the compounds into the dorsal raphe area resulted in alterations of prolactin and LH release, the analogue caused elevation of prolactin and inhibition of LH release, whereas the opiate antagonist resulted in opposite changes. Only an LH response was obtained from the hypothalamic dorsomedial nucleus and a growth hormone response from the central amygdala. Also in these cases the enkephalin analogue decreased LH and elevated growth hormone plasma levels, and naloxone brought about a rise in LH and a diminution of growth hormone concentration. None of the regions were effective in inducing a clear-cut adrenocorticotrophin or follicle-stimulating hormone response. The parietal cortex, medial amygdala and the dentate gyrus were entirely ineffective sites. The findings suggest that in the brain there are multiple sites of action of opioids on pituitary trophic hormone secretion and the effective sites are not identical in terms of pituitary hormone response.
Collapse
Affiliation(s)
- J Molnár
- Second Department of Anatomy, Semmelweis Medical University, Tuzolto utca 58, H-1094 Budapest, Hungary
| | | | | |
Collapse
|
34
|
Kapoor R, Willoughby JO. Activation of opioid receptors in the mediobasal hypothalamus stimulates prolactin secretion in the conscious rat. J Neuroendocrinol 1990; 2:347-50. [PMID: 19215358 DOI: 10.1111/j.1365-2826.1990.tb00416.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Abstract In an attempt to localize the opioid receptor(s) (mu, delta and kappa) involved in opioid-stimulated prolactin release in the conscious male rat, opioid agonists were microinjected into the mediobasal hypothalamus and prolactin levels measured before and after injection. The specific mu agonist, DAGO ((D-Ala(2), NMe-Phe(4), Gly-ol(5))-enkephalin) was the most effective in eliciting prolactin release, the smallest effective dose being 0.01 nmoles. The specific delta agonist, DPDPE ((D-Pen(2), D-Pen(5))-enkephalin) had no significant effect even at the highest dose of 10 nmoles. The specific kappa agonist, U50,488H ((trans-3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzene acetamide) was effective at the doses 1.0 and 10 nmoles. We conclude that mu and kappa opioid receptors in the mediobasal hypothalamus are involved in opioid-stimulated prolactin release and that delta receptors are not.
Collapse
Affiliation(s)
- R Kapoor
- Centre for Neuroscience and Department of Medicine, Flinders Medical Centre, Bedford Park, South Australia, 5042
| | | |
Collapse
|
35
|
Abstract
Abstract The fact that opiates elicit prolactin secretion is well known. However, we have recently discovered that morphine does not stimulate prolactin release in lactating rats. The physiological basis for this alteration in opiate sensitivity during lactation is not known. Since morphine-induced prolactin secretion in male rats is mediated via the mu opioid receptor subtype, one possible explanation is that mu receptors are down-regulated during lactation. To address this possibility, the effects of mu opioid peptides on prolactin secretion were examined in lactating rats. The presumed mu-selective peptides DAGO ([D-Ala(2), Me-Phe(4), Gly-ol(5)]-enkephalin) and PLO-17 ([NMe-Phe(3), D-Pro(4)]-morphiceptin) were administered to primiparous lactating rats and the resulting hormone responses measured. Both DAGO and PLO-17 caused a rapid and significant rise in plasma prolactin during lactation. The prolactin-releasing effects of both peptides were naloxone reversible, suggesting involvement of opioid receptors. Moreover, the DAGO-induced secretion of prolactin could be completely abolished by pretreatment with the irreversible mu antagonist beta-funaltrexamine. In lactating rats, DAGO and PLO-17 were poor growth hormone-releasing agents, providing further evidence for the mu specificity of these peptides. These results imply that during lactation, as in other reproductive states, mu opioid receptor sites are positively coupled to the prolactin secretory mechanism. Thus, the previously observed inability of morphine to elicit prolactin release in lactating rats cannot be explained on the basis of down-regulation of mu opioid receptors.
Collapse
Affiliation(s)
- M H Baumann
- Department of Biological Sciences and the Bureau of Biological Research, Rutgers University, Piscataway, New Jersey 08855, USA
| | | |
Collapse
|
36
|
Codd EE, Aloyo VJ, Walker RF. A non-opioid pattern characterizes inhibition of growth hormone releasing peptide binding by dynorphin-related peptides. Neuropeptides 1990; 15:133-7. [PMID: 1979153 DOI: 10.1016/0143-4179(90)90144-n] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-LysNH2; SK&F 110679) is a hexapeptide that specifically releases growth hormone. Although derived from methionine enkephalin, 3H-SK&F 110679 binding profiles suggest that it retains little mu or delta opioid activity. In the present study, dynorphin A was a potent inhibitor of SK&F 110679 binding. However, detailed structure-activity studies using dynorphin-related compounds suggest that the interaction between SK&F 110679 and dynorphin was non-opioid in nature. The non-opioid peptide des-Tyr-dynorphin was virtually as potent an inhibitor of 3H-SK&F 110679 binding as the intact dynorphin peptide. Additionally, the non-peptide, kappa selective ligand U-50,488 was a very weak inhibitor of 3H-SK&F 110679 binding. Since dynorphin but not U-50,488 has been reported to release growth hormone, the present results suggest that a non-opioid dynorphin site participates in SK&F 110679's growth hormone releasing action.
Collapse
Affiliation(s)
- E E Codd
- R. W. Johnson Pharmaceutical Research Institute, Department of Biological Science, Springhouse, PA 19477-0776
| | | | | |
Collapse
|
37
|
Gulya K. The opioid system in neurologic and psychiatric disorders and in their experimental models. Pharmacol Ther 1990; 46:395-428. [PMID: 2188270 DOI: 10.1016/0163-7258(90)90026-x] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Evidence from experimental and clinical studies suggests the involvement of the endogenous opioid system in several neurologic and psychiatric disorders (Alzheimer's, Huntington's and Parkinson's diseases, drug-induced movement disorders, Gilles de la Tourette syndrome, stroke, ischemia, brain and spinal cord injury, epilepsy, schizophrenia and affective disorders). However, its involvement is rather a secondary one, perhaps being a severe consequence of a primary, nonopioid disturbance. Thus, treatment of an opioidergic manifestation of a disorder of nonopioidergic origin is necessarily symptomatic and targets only the restoration of the opioid system; such treatment may be beneficial in ameliorating the clinical symptoms of the disorder.
Collapse
Affiliation(s)
- K Gulya
- Central Research Laboratory, Albert Szent-Györgyi Medical University, Szeged, Hungary
| |
Collapse
|
38
|
Zagon IS, Zagon E, McLaughlin PJ. Opioids and the developing organism: a comprehensive bibliography, 1984-1988. Neurosci Biobehav Rev 1989; 13:207-35. [PMID: 2691928 DOI: 10.1016/s0149-7634(89)80055-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
A comprehensive bibliography of the literature concerned with opioids and the developing organism for 1984-1988 is presented. Utilized with companion papers (Neurosci. Biobehav. Rev. 6:439-479; 1982; 8:387-403; 1984), these articles cover the clinical and laboratory references beginning in 1875. For the years 1984, 1985, 1986, 1987, and 1988, a total of 877 citations were recorded. A series of indexes accompanies the citations in order to make the literature more accessible. These indexes are divided into clinical and laboratory topics, and subdivided into such topics as the type of opioid explored and the general area of biological interest (e.g., physiology).
Collapse
Affiliation(s)
- I S Zagon
- Department of Anatomy, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey 17033
| | | | | |
Collapse
|
39
|
Martini L, Dondi D, Limonta P, Maggi R, Piva F. Modulation by sex steroids of brain opioid receptors: implications for the control of gonadotropins and prolactin secretion. JOURNAL OF STEROID BIOCHEMISTRY 1989; 33:673-81. [PMID: 2557489 DOI: 10.1016/0022-4731(89)90477-9] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Several experiments have been performed in order to analyze whether physiological or experimental changes of the endocrine environment might modify the binding characteristics of brain mu and kappa opioid receptors in the brain of the female and male rat. (a) In a first series of experiments, it has been observed that in the whole brain of regularly cycling female rats the number of mu receptors shows variation during the different phases of the estrous cycle. In particular a significant increase of the number of mu receptors has been observed in the morning of proestrus and in the afternoon of estrus. (b) In a second series of experiments, it has been shown that the administration of estrogens brings about a significant increase in the number of mu receptors in the hippocampus and in the thalamus of ovariectomized rats, while the administration of a regime including estrogen and progesterone induces a significant decrease of the number of mu receptors in the hypothalamus and in the corpus striatum. These data seem to indicate that hypothalamic mu receptors may be involved in the positive but not in the negative feedback control of LH secretion. (c) In a third series of experiments, it has been found that the number of mu receptors in the whole brain of 15- and 22-month-old male rats and in the hypothalamus of 22-month-old male rats is significantly lower than in the same tissues of young animals; moreover, the administration to old animals of testosterone does not modify the number of hypothalamic mu opioid receptors, indicating that the decline of brain mu receptors in old animals is not the consequence of the physiological decline of testosterone secretion but probably represents an autonomous phenomenon. (d) In a fourth series of experiments, it was shown that, in young male rats, the concentration of kappa receptors is extremely variable in different regions of the brain. The highest concentrations have been found in the hypothalamus and in the striatum; also in the mesencephalon and in the amygdala kappa receptors are present in rather elevated quantities; lower concentrations have been found in the thalamus, the frontal poles, the hippocampus and in the anterior and posterior cerebral cortex. These experiments have shown in addition that the process of aging induces an increase of the number of kappa receptors in the amygdala and in the thalamus; no age-linked modifications were observed in the other structures examined.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- L Martini
- Department of Endocrinology, University of Milano, Italy
| | | | | | | | | |
Collapse
|
40
|
Abstract
The hypothalamus receives neuronal afferents from numerous sources including inputs from limbic structures, such as the amygdala and hippocampus, and from brainstem regions involved in the regulation of the cardiovascular system and other autonomic functions. These afferents using a vast array of neurotransmitters and neuropeptides influence the activity of the hypothalamic neurons which synthesize and secrete the hypothalamic releasing and release-inhibiting factors into the hypophyseal portal circulatory system. The afferents can modulate the activity of the hypothalamic neurons by forming synapses on the neuronal cell body, on the nerve terminals in the median eminence or both. The chemicals most frequently used as neurotransmitters are the biogenic amines, including the catecholamines (norepinephrine, dopamine and epinephrine), serotonin, acetylcholine and gamma-aminobutyric acid (GABA). The stimulatory influence of norepinephrine, serotonin, and acetylcholine on the secretion of corticotropin (ACTH) in rodents and man will be discussed, whereas GABA exerts an inhibitory effect on the secretion of ACTH in both man and rodents. These effects appear to be mediated by changes in the secretion of the corticotropin-releasing hormone (CRH) and vasopressin into the hypophyseal portal circulation. Numerous neuropeptides appear to alter the secretion of ACTH in the rat. We will discuss the stimulatory actions of neuropeptide Y (NPY), angiotensin II, and peptides of immune cell origin on the secretion of ACTH and CRH. The opioid peptides inhibit the secretion of CRH into the portal blood, however, they exert a potent stimulatory effect on prolactin secretion in the rat and man.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- J I Koenig
- Neurology Service, Massachusetts General Hospital, Boston
| |
Collapse
|
41
|
Abstract
An attempt is made to deal with the complexity of the nerve fibers in the median eminence. Visual aids are presented in the shape of "wheels" that depict a dynamic interplay of neurochemicals which result in the release of hormones from the anterior pituitary gland. The multiplicity of neurochemicals in the median eminence is perceived to be responsible for the integrated control of pituitary hormone releasing factors.
Collapse
Affiliation(s)
- D M Jacobowitz
- Laboratory of Clinical Science, National Institutes of Mental Health, Bethesda, Maryland 20892
| |
Collapse
|
42
|
Buydens P, Govaerts J, Velkeniers B, Finné E, Vanhaelst L. The effect of bombesin on basal, alpha-methyl-p-tyrosine, haloperidol, morphine, bremazocine and stress-induced prolactin secretion. Life Sci 1988; 43:1755-60. [PMID: 2904106 DOI: 10.1016/0024-3205(88)90488-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Intravenously administered bombesin lowered basal PRL levels in conscious male rats and prevented the morphine, bremazocine and stress-induced PRL secretion. The same dose of bombesin had no effect on PRL levels in alpha-methyl-p-tyrosine pretreated rats and did not affect haloperidol-stimulated PRL release. These results show that bombesin given intravenously acts as an inhibitor of PRL secretion and suggests that it does not act on the lactotrope itself but rather by an increase of the inhibitory dopaminergic tone.
Collapse
Affiliation(s)
- P Buydens
- Pharmacology Unit, School of Medicine, University of Brussels, Belgium
| | | | | | | | | |
Collapse
|
43
|
Callahan P, Janik J, Rabii J. Time course of the insensitivity of prolactin release to morphine administration in the lactating female rat. Life Sci 1988; 43:49-57. [PMID: 3386414 DOI: 10.1016/0024-3205(88)90236-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The effect of morphine on circulating levels of prolactin and growth hormone (GH) in the lactating female model was determined at various time intervals following the termination of suckling. Morphine administration did not produce an increase in prolactin levels when dams remained suckling. Four days after suckling was terminated, 50% of the dams tested showed a morphine induced prolactin increase. The prolactin secretory response to morphine gradually returned in dams, so that after 8 days of non-suckling, all animals tested showed a morphine induced prolactin increase. Consistent with the lack of prolactin stimulation, the tuberoinfundibular dopaminergic (TIDA) neurons, were insensitive to the morphine induced inhibition of activity during lactation. In contrast, circulating levels of GH were increased in these dams following morphine administration. These results suggest that the lactating female rat is insensitive to the mu mediated stimulation of prolactin release while suckling. However, sensitivity begins to return following at least 4 days of non-suckling.
Collapse
Affiliation(s)
- P Callahan
- Department of Biological Sciences, Rutgers University, Piscataway, New Jersey 08855
| | | | | |
Collapse
|
44
|
Bero LA, Lurie SN, Kuhn CM. Early ontogeny of kappa-opioid receptor regulation of prolactin secretion in the rat. Brain Res 1987; 465:189-96. [PMID: 2894234 DOI: 10.1016/0165-3806(87)90240-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Although both mu- and kappa-opioid components of prolactin (PRL) secretion have been identified in the adult rat, the neural pathways through which these multiple receptor subtypes modulate PRL secretion have not been thoroughly investigated. The present study utilizes the differential ontogeny of opioid systems which alter PRL release to examine the mechanisms by which mu- and kappa-receptors regulate prolactin. The responses of PRL, corticosterone and growth hormone to opioid receptor subtype-specific agonists were studied in neonatal rats. The PRL response to the kappa-agonist, U50488, preceded the response to the mu-agonist, morphiceptin. Like adults, neonates demonstrated a growth hormone, but not a PRL, response to the delta agonist, [D-pen2,pen5]enkephalin. U50488-induced PRL secretion was not attenuated by cyproheptadine in adults or neonates, suggesting that the kappa-opioid mechanism operates independently of serotonin. In contrast, the PRL response to morphine was attenuated in adult rats. In addition, U50488 decreased median eminence dopamine synthesis in both adults and neonates. These findings suggest that the early developing, serotonin-independent opioid regulation of PRL is mediated through kappa-receptors, while the later-developing mechanism which requires intact serotonergic transmission works through mu-receptors. kappa-Receptors appear to regulate PRL secretion by directly inhibiting the activity of tuberoinfundibular dopamine neurons, while mu-receptors might regulate the tonic dopaminergic inhibition of PRL through a serotonergic pathway.
Collapse
MESH Headings
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer
- Animals
- Dynorphins/pharmacology
- Endorphins/pharmacology
- Enkephalin, D-Penicillamine (2,5)-
- Enkephalins/pharmacology
- Hydrazines/pharmacology
- Morphine/pharmacology
- Peptide Fragments/pharmacology
- Prolactin/metabolism
- Pyrrolidines/pharmacology
- Rats
- Rats, Inbred Strains
- Receptors, Opioid/drug effects
- Receptors, Opioid/physiology
- Receptors, Opioid, kappa
- Receptors, Opioid, mu
- Serotonin/pharmacology
Collapse
Affiliation(s)
- L A Bero
- Department of Pharmacology, Duke University Medical Center, Durham, NC 27710
| | | | | |
Collapse
|
45
|
Millan MJ, Morris BJ, Colpaert FC, Herz A. A model of chronic pain in the rat: high-resolution neuroanatomical approach identifies alterations in multiple opioid systems in the periaqueductal grey. Brain Res 1987; 416:349-53. [PMID: 3040180 DOI: 10.1016/0006-8993(87)90917-6] [Citation(s) in RCA: 31] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Inoculation of the tail base of rats with Mycobacterium butyricum led to an arthritic swelling and inflammation of the limbs which displayed a hyperalgesia to noxious pressure: these effects peaked at 3 weeks postinoculation. In vitro autoradiography of coronal sections of rat brain was used for a parallel determination of binding to mu-, delta- and kappa-opioid binding sites. In only two regions, the dorsomedial and dorsolateral parts of the periaqueductal grey (PAG), was a significant change seen: this comprised an increase in binding to kappa-sites, whereas mu- and delta-sites therein were unaffected. This region was analysed for opioid peptides derived from each of the three opioid peptide families known. While no change was seen in levels of immunoreactive (ir)-dynorphin1-17 A (DYN) and ir-Met-enkephalin, a decrease was detected in those of ir-beta-endorphin (beta-EP): this change was restricted to the PAG. These data demonstrate a highly localized and selective influence of chronic arthritic pain upon multiple opioid systems in the PAG of the rat, a structure playing a key role in the control of pain and in the expression of the antinociceptive actions of opioids. The data suggest a possible significance of PAG pools of beta-EP and kappa-receptors in the response to and modulation of chronic pain.
Collapse
|
46
|
Limonta P, Maggi R, Dondi D, Martini L, Piva F. Gonadal steroid modulation of brain opioid systems. JOURNAL OF STEROID BIOCHEMISTRY 1987; 27:691-8. [PMID: 2826902 DOI: 10.1016/0022-4731(87)90138-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
It is becoming increasingly clear that the effects of the opioids and their synthetic analogs on anterior pituitary function largely depend on the steroid milieu present in the animal at time of drug administration. However, it is still unclear whether gonadal steroids regulate the opioid-modulated mechanisms by affecting the number of opiate receptors in the brain. To further investigate these issues, the effects of opiate agonists and antagonists on LH, FSH and prolactin (Prl) secretion have been studied in: (a) normal and castrated male rats, and (b) normally cycling female rats. The binding characteristics of the brain subclass of mu opiate receptors have been analyzed in the same group of experimental animals; this type of receptors seems to be particularly involved in the control of gonadotropin and Prl release. When injected intraventricularly into normal male rats, morphine (200 micrograms/rat) induced in a significant elevation of serum LH levels at 10 and 20 min. In long-term castrated animals the administration of the drug significantly reduced LH secretion at 40 and 60 min after the injection, the inhibition lasted up to 180 min. Morphine, when given intraventricularly to normal males, induced a conspicuous and significant elevation of serum Prl levels at 10, 20, 40 and 60 min after treatment. However, when the drug was administered to castrated rats, it did not significantly affect Prl release at any time interval considered. Morphine intraventricular injections did not modify serum FSH levels either in normal or in castrated male rats. The concentration of mu opiate receptors was found to be similar when measured in the whole brain of normal and orchidectomized rats. In adult cycling female rats, s.c. injections of naloxone (2.5 mg/kg) stimulated LH release in every phase of the estrous cycle; the magnitude of the responses was highly variable, being particularly elevated at 16.00 h of the day of proestrous and at 10.00, 12.00 and 14.00 h of the day of estrous. Conversely, LH response to naloxone was totally obliterated at 18.00 and 20.00 h of the day of proestrous, when the preovulatory LH surge was found to occur. The concentration of brain opiate receptors of the mu type showed significant variations during the different phases of the estrous cycle, with higher levels at 12.00 h of the day of proestrous and at 18.00 h of the day of estrous.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- P Limonta
- Department of Endocrinology, Milano, Italy
| | | | | | | | | |
Collapse
|
47
|
Martini L, Dondi D, Limonta P, Maggi R, Motta M, Piva F. Peptide-steroid interactions in the modulation of the hypothalamic-pituitary axis. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 1987; 219:3-20. [PMID: 2829577 DOI: 10.1007/978-1-4684-5395-9_1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- L Martini
- Department of Endocrinology, University of Milano, Italy
| | | | | | | | | | | |
Collapse
|
48
|
Abstract
Plasma concentrations of growth hormone (GH) were decreased following the intravenous administration of morphine sulfate. Maximum inhibition of GH secretion was observed 40 min after morphine sulfate challenge. At this time, doses of morphine sulfate (at 5 mg and 50 mg/kg) reduced the GH concentrations by 86 and 90%, respectively, in comparison with those in the vehicle-injected controls. An opiate antagonist, naloxone, had no stimulatory effect on basal GH concentrations, but attenuated the GH response to morphine. Neither morphine nor naloxone had any significant effect on circulating luteinizing hormone (LH) levels. These results indicate an inhibitory opiate pathway in the control of GH release and demonstrate effects on GH and LH secretion contrary to those observed in mammalian species.
Collapse
|